Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Pharmaceutical Statistics|March 15, 2020
Revisit of test-then-pool methods and some practical considerationsWen Li, Frank Liu, Duane SnavelyStatistics in Medicine|September 5, 2009
An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding studyAnastasia Ivanova, Ken Liu, Ellen Snyder, et al.Statistics in Medicine|May 4, 2004
The role of the unblinded sponsor statisticianSteven Snapinn, Thomas Cook, Deborah Shapiro, et al.Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|March 3, 2010
Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studiesThomas Roth, Christopher Lines, Kristel Vandormael, et al.Schizophrenia Research|March 26, 2013
Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophreniaMichael F Egan, Xin Zhao, Regina Gottwald, et al.Neurology|December 1, 2012
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexantW Joseph Herring, Ellen Snyder, Kerry Budd, et al.Sleep Medicine|August 8, 2013
Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover studyW Joseph Herring, Kenneth Liu, Jill Hutzelmann, et al.Journal of Clinical Pharmacology|June 24, 2003
Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairmentTania Z Dickson, JoAnn Zagrobelny, Charles C Lin, et al.Biological Psychiatry|October 27, 2005
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorderMartin Keller, Stuart Montgomery, William Ball, et al.The International Journal of Neuropsychopharmacology|March 17, 2016
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary InsomniaKathryn M Connor, Erin Mahoney, Saheeda Jackson, et al.Pageof 2